For information regarding Hospital Medicine 2018, please click here .

Inpatient Glycemic Control With Basal-Bolus Insulin: 2017 Update

Hospital medicine programmes often combine complex illness with rapidly changing nutrition, medications and organ function. For people with diabetes, that combination can make inpatient glycemic control using basal-bolus insulin regimens both effective and hazardous. Scheduled basal insulin, mealtime doses and correction doses can better reflect physiology than relying on sliding-scale insulin alone, but safety depends on accurate assessment, clear targets and reliable monitoring.

The 2017 conference update focused on translating these principles into daily ward practice. For Australian teams, this means balancing evidence-based regimens with local formulary choices, pharmacy support, equipment availability and the needs of culturally and geographically diverse patients. The strongest approach treats glycaemic management as a coordinated clinical process rather than an isolated insulin order.

Clinical context Common insulin approach Monitoring focus Important limitation
Stable ward patient eating Basal insulin with mealtime and correction doses Meals, glucose pattern and hypoglycaemia Orders must match intake and activity
Nil by mouth or preparing for surgery Basal dose may be reduced or held Frequent bedside glucose checks No mealtime insulin without an eating plan
Critical illness Intravenous insulin infusion is often preferred Hourly glucose adjustment Basal-bolus regimens may add complexity
Kidney disease Adjust and monitor insulin cautiously Longer trends, renal function and hypo risk Reduced clearance can prolong insulin action

Why glycaemic management changed by 2017

By 2017, the main criticism of sliding-scale insulin was its inability to anticipate meals, overnight needs or changes in insulin sensitivity. Correction doses responded to hyperglycaemia after it had developed, potentially producing a pattern of rising glucose followed by treatment-related hypoglycaemia. Basal-bolus regimens addressed this by separating fasting requirements from the glucose load associated with food.

Hospitalisation itself alters glucose handling through stress hormones, infection, reduced activity, altered appetite and interruptions to outpatient medicines. A basal dose maintains a predictable background level, while mealtime insulin is matched to carbohydrate intake. Correction doses provide a safety net when glucose remains above the agreed range, provided they are used with appropriate monitoring and not as a substitute for reviewing the underlying pattern.

The update also emphasised that no single protocol suits every ward. A regimen suitable for a stable patient eating regularly may be inappropriate during fasting, critical illness, advanced kidney disease or palliative care. Local protocols must therefore define when basal-bolus therapy should start, when it should be simplified and when specialist diabetes support is required.

Building a basal-bolus regimen

Assessment should begin before the first dose. Teams need the person’s usual insulin, mealtime pattern, HbA1c, recent glucose profile, food intake, weight, renal and liver function, and relevant medicines such as steroids or antidiabetic tablets. HbA1c offers useful background information, but it does not show inpatient glycaemic variability and may be misleading in some anaemias, kidney diseases or recent blood transfusions.

Basal insulin may be NPH or a long-acting analogue, while mealtime treatment can use regular or rapid-acting insulin. The basal component must align with the expected fasting period and any overnight clinical review. Prandial doses should follow the meal plan rather than precede an uncertain period of nil by mouth. Australian teams often refer to this as matching insulin to “eat and test” behaviour, with carbohydrate intake and appetite documented alongside each dose.

Correction scales should be individualised and linked to the patient’s pattern of response. An unexplained rise may reflect an interrupted meal, infection, missed basal dose, medication change or reduced insulin effectiveness. Reviewing that context is safer than repeatedly increasing a correction dose. Any unexplained hypoglycaemia should prompt review of basal insulin, oral intake, renal function and the timing of medicines.

Targets, monitoring and special situations

Many Australian hospital protocols use a glucose target of approximately 4–8 mmol/L for non-critically ill inpatients. Tighter control is not automatically safer, especially when food intake is unreliable or the patient has impaired awareness of hypoglycaemia. Critical illness, pregnancy, advanced frailty and goals of care may require different targets, so those exceptions should be stated explicitly rather than left to individual interpretation.

Bedside glucose testing should occur at mealtimes, bedtime and additional times dictated by the regimen or clinical condition. More frequent checks are needed when insulin is being adjusted, after a missed meal or during acute illness. Continuous glucose monitoring can reveal patterns hidden by intermittent testing, although in 2017 it was not routine in most Australian hospitals and did not remove the need for insulin safety checks.

Patients who are nil by mouth, preparing for surgery or receiving enteral feeds require a specific plan. Basal insulin may need adjustment during prolonged fasting, while prandial doses are usually unnecessary without food. Enteral feeding regimens vary because the rate, composition and interruptions of feeds determine glucose patterns. Steroid-treated patients may need proactive adjustments rather than waiting for marked hyperglycaemia, while those with chronic kidney disease require close observation because insulin clearance and glycaemic response can be less predictable.

Fitting care into Australian hospitals

In Australian public hospitals, medication charts, ward pharmacy services and multidisciplinary reviews shape how regimens are implemented. During the “ward round,” the medical team, nurse, dietitian and pharmacist may each hold part of the glycaemic picture. Electronic medication records and bedside barcode checking can reduce transcription errors, but they cannot compensate for an unclear meal plan or mismatched target range.

Geography adds another layer. In rural and remote hospitals, diabetes educators and specialist teams may be available through telehealth rather than on site. Medication supply, refrigeration, blood glucose meters and timely pathology results can also depend on distance from major centres. Standardising basal products, providing clear escalation pathways and maintaining spare equipment are practical safety measures rather than administrative details.

Discharge planning must account for affordability and access. Inpatient medicines are generally supplied by the hospital rather than the Pharmaceutical Benefits Scheme, while outpatient insulin after discharge may require PBS funding or private insurance arrangements. The discharge script, community follow-up and any changes to the patient’s usual basal or mealtime routine should be reconciled before departure. For Aboriginal and Torres Strait Islander patients, family involvement, interpreter support and respectful discussion of food security are central to preventing readmission.

Capacity, consent and medication safety

Insulin decisions may require assessment of the patient’s capacity to understand and weigh the options, particularly when cognitive impairment, delirium, severe illness or conflicting treatment preferences are present. Capacity is decision-specific and can fluctuate. A patient who cannot choose a complex insulin regimen may still be able to express preferences about food, timing or where care should occur, and those preferences should remain part of the plan. The discussion of capacity assessment workshop illustrates why clinical reasoning and ethics need to sit alongside the medication chart.

Insulin is a high-alert medicine because a small dose error can cause severe harm. Independent checks are particularly important for concentrated insulin, insulin pumps and transitions between basal products. Orders should specify the product, dose, timing and indication, while the medication administration record should show whether a meal was actually eaten. Regular review of hypoglycaemia, unexplained hyperglycaemia and deviations from the prescribed regimen can reveal system problems rather than individual error.

Translating conference learning into practice

Hospital Medicine 2017 took place from 1–4 May at Mandalay Bay Resort and Casino in Las Vegas, bringing hospitalists and other healthcare professionals together around research, patient care, quality improvement and professional development. The conference programme offered access to educational resources and continuing medical education alongside opportunities for professional networking.

For Australian delegates and virtual participants, the useful outcome was not a single protocol but a method for adapting evidence locally. A glycaemic improvement project could compare insulin orders with meal delivery, document bedside testing quality and identify common sources of hypoglycaemia. Findings could then be discussed with nursing, pharmacy, dietetic and consumer representatives before changes were introduced across the hospital.

Local adaptation also requires attention to outcomes. Teams should monitor severe hypoglycaemia, insulin-related readmissions, medication errors and the proportion of patients whose regimen matches their intake and monitoring plan. Education is most effective when it uses real ward cases, reflects Australian terminology and provides clear escalation contacts, including after-hours pathways for rural hospitals.

A practical implementation checklist

A reliable basal-bolus programme needs shared rules about assessment, prescribing, monitoring and review. The following measures create a practical foundation for ward implementation:

  • Start every regimen with a documented review of prior insulin, oral intake, HbA1c, renal function, medicines and the patient’s ability to manage the regimen.
  • State the glucose target, timing of basal and mealtime doses, meal plan and action for missed meals or elevated glucose directly on the medication chart.
  • Use a validated correction scale with regular review of patterns, and avoid automatic dose increases when the likely cause has not been assessed.
  • Build multidisciplinary access into the ward workflow, including pharmacy review, diabetes educator support, telehealth escalation and structured discharge reconciliation.
  • Audit hypoglycaemia, hyperglycaemia, late corrections and insulin errors to identify whether the problem lies in orders, workflow, equipment or clinical deterioration.

Education should reach everyone involved in administration and monitoring, not only prescribers. Short case-based sessions can cover basal insulin products, meal timing, sick-day management, pump safety and the management of hypo events. Patients and families should receive a plain-English discharge summary that explains dose changes and includes a clear contact for advice after leaving hospital.

The next scheduled multidisciplinary insulin review will examine one patient’s basal dose, meal pattern, renal function and discharge medicines, then document one agreed adjustment in the medication record before that patient leaves the ward.

  • Re-energize and focus your practice with the latest research, best practices and newest innovations in the field that can immediately be applied to improving patient care.
  • Learn from the “best of the best,” including nationally renowned leaders in the field of hospital medicine.
  • Connect and collaborate with a vibrant community of hospital medicine professionals.